Search Results

In this study, we are going to compare two ways of treating mild respiratory illnesses in children with Cystic Fibrosis (CF). One is immediate antibiotics (increase airway clearance and start oral antibiotics right away) and the other is tailored therapy (increase airway clearance right away but only start oral antibiotics if symptoms worsen or do not improve). We are looking at how safe each option is and how well each one works. To do this, we will randomize participants (like flipping a coin) to one of these two approaches if a mild respiratory illness happens over the next 12 months.

This study is comparing the treatment of Non-Alcoholic Steatohepatitis (NASH) with either lifestyle changes or obesity surgery with lifestyle changes.  Participants must be 30-70 years old, have a BMI of 35.0-60.0 kg/m2, have health insurance that will pay for obesity surgery, and be willing to accept either treatment.

The goal of this study is to develop and test a new way of measuring how much effort and strain the jaw muscles can handle before a person begins to feel specific levels of pain or fatigue. This involves a controlled jaw exercise task designed to better understand the relationship between jaw muscle effort, physical stress in the muscles, and how each person experiences discomfort. It is hoped that the information learned in this study will help researchers refine this new jaw testing method and confirm whether it accurately measures jaw muscle effort and discomfort. This may support future research that improves how jaw pain conditions are understood and eventually lead to better, more individualized treatments for people with jaw muscle and jaw joint disorders.

The purpose of this study is to evaluate the effectiveness of investigational devices (the Lilac Glove and Lilac Boot devices) for the temporary reduction of moderate to severe symptoms of peripheral neuropathy caused by chemotherapy during the treatment of cancer. The Lilac Glove and Lilac Boot devices are designed to keep chemotherapy medication from damaging nerves. The study involves wearing the Lilac Glove and Boot devices on both hands and feet at each treatment session. Participants will be randomly assigned (like the flip of a coin) into one of two treatment groups; the “intervention group” (which means you receive treatment with the therapeutic Lilac devices) or the “control group” (which means you will receive treatment with the sham devices).

The treatment (chemotherapy and transplant procedures) is considered standard clinical care that are usually given to the patients with this disease. The research aspect of this study is to collect data on the patients who are being treated on this plan. Patients will be followed throughout the course of their clinical care and for three years after their transplant.

This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.

The purpose of this research is to collect, store and distribute specimens and information about people with solid tumors. Samples from many people are being collected and stored so they can be used for research now and in the future.

This study collects MRI brain scans before, during, and after treatment in people with depression and other mental health conditions who are receiving neuromodulation therapies. The goal is to see whether differences in brain structure can help explain why some people respond to treatment better than others.

This study is looking at a new, non-invasive treatment approach for people who continue to have symptoms after a mild traumatic brain injury (such as a concussion). The treatment combines gentle brain stimulation with cognitive training exercises. The goal of the study is to see whether this combined approach can help improve thinking, memory, and overall daily functioning in individuals with persistent post-concussion symptoms. To see if you may be eligible, complete the screening form by selecting the "Visit the Study Website" button.

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The study entails 2 visits over a 3-month period. On enrollment, participants will be scheduled for the 2 visits, during which fasting blood samples will be collected.

This trial is testing MK-5684 in men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation Hormonal Agent (NHA) and Taxane-based chemotherapy. This trial will compare MK-5684 to abiraterone acetate and enzalutamide. Abiraterone acetate and enzalutamide are standard treatments for mCRPC. The purpose of this trial is to test the safety of the trial drug, MK-5684, see how well the drug works, and see how the body handles the drug. We also want to see if participants who get MK-5684 live longer compared to those who get abiraterone acetate or enzalutamide.

This study is designed to better understand the mechanisms contributing to impaired activation of leg muscles in people with Parkinson’s disease (PD) and test if stimulation of a nerve at the neck (vagus nerve) can improve muscle activation, walking and balance. People can participate in one of two experiments, or both. Both experiments will test the muscle activation patterns in the lower leg when producing low levels of force. We will also assess walking and balance. Experiment 2 will test muscle activation patterns, walking and balance before and after vagus nerve stimulation. We are also asking people who don’t have PD and are 21 to 76 years old and match in age and sex to participants to undergo the same study procedures.

This study will look at the effects of treatment combining Comprehensive Behavioral Intervention for Tics (CBIT) and Transcranial Magnetic Stimulation (TMS) for young people who have tic disorder. Participants must be 12- 21 years old and able to have an MRI. All participants will receive 10 daily sessions of CBIT, a well-established behavioral treatment that is considered to be the first treatment for tics. Participants will also be assigned randomly (by chance) to receive TMS or a sham (treatment not delivered) just before each CBIT session. The device for TMS delivers electromagnetic stimulation to a specific area of the brain with a small coil on the scalp. The effectiveness of the CBIT for the two groups, with and without the TMS, will be compared.

Former smokers continue to be at higher risk for developing lung cancer than non-smokers,even years after quitting. This study will look at how a specific chemical, phenanthrene, is broken down in the lungs of former smokers and non-smokers. If former smokers break down chemicals in a more harmful way, it might help explain their increased risk for lung cancer. Study participants will be asked to attend an in-person study visit to vape a small amount of phenanthrene and then collect their urine for 24 hours afterwards.

This clinical research study is being conducted to gain knowledge about a new drug called BAY 2927088 for a type of cancer called advanced non-small cell lung cancer, which cannot be removed with surgery or has spread to other parts of the body, and has a mutation in the HER2 gene.

This study is being done to develop a way to use information from a continuous glucose monitor (CGM) to predict a person’s progression through the Stages of Type 1 Diabetes (T1D). A CGM is a wearable device that continuously measures and displays a person’s blood sugar levels throughout the day and night by sensing the glucose (blood sugar levels) in the fluid under the skin, providing real-time updates without the need for finger pricks.

The goal of this study is to evaluate nemtabrutinib compared with either ibrutinib or acalabrutinib for treatment of people with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy.

The purpose of this study is to find the best dose of NXC-201 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment. NXC-201 is a cellular therapy made from your own white blood cells called T cells. If you join this study, we will collect some of your T cells and modify (change) them in a lab. This modification will help your T cells find and kill abnormal plasma cells. These genetically changed T cells are called chimeric antigen receptor (CAR) T cells. NXC-201 is a CAR T cell therapy and is given intravenously (by vein). To prepare your body for NXC-201, you will also get fludarabine and cyclophosphamide, which are chemotherapy drugs. After you get NXC-201, you will be in the hospital for at least 10 days.

We’re studying disitamab vedotin to find out what its side effects are and if it works for urothelial cancer when given with pembrolizumab. We want to see if these drugs work better together than the available approved treatments.

Medications used to treat Parkinson's disease will be delivered using a sachet ; placed in the oral/buccal cavity (between cheek and gum of lower jaw). This study may be a good fit for you if you are healthy, between the ages of 18 and 65, and aren’t currently taking regular medications. We expect that you will be in this research study for one visit, approximately 7 hours total. Compensation and transportation expenses will be provided.

This study aims to test the accuracy and speed of the pABR for future clinical use by recruiting infants and adults with a range of hearing loss profiles from normal hearing to severe loss.

This study compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

This research study is being done so that we can better understand why women with post-traumatic stress disorder (PTSD) may have higher risk of cardiovascular disease as they get older. This study looks at how trauma and PTSD affect blood vessels in young women. The study is also testing whether a dietary supplement called beetroot juice might help improve the function of blood vessels in women suffering from PTSD. Study participation involves coming to the University of Minnesota campus in Minneapolis for two visits. Each of the visits with take about 3 and a half hours.

We are investigating ways to improve methods of brain stimulation. The purpose of this study is to try a new way to deliver transcranial magnetic stimulation (TMS) to the brain. Participants will be asked to come in for three separate 4-hour research visits. Each research visit will take place approximately seven days after the previous one. During the research visits, we will put a mesh cap on the head to measure electrical activity in the brain (also known as an EEG). Once the cap is on, we will use a transcranial magnetic stimulation (TMS) device to deliver small pulses of electricity to the brain to see how it reacts to the stimulation.

This study is being done to learn more about maridebart cafraglutide (MariTide [formerly AMG 133]) for people with heart failure (HF) and obesity in addition to their routine medical care. Participants will receive treatment with either MariTide or a placebo, which will be called a study drug. A placebo looks the same as the investigational medicine but contains no actual medicine.

The purpose of this study is to evaluate the ability of a device (Vocxi Health’s MyBreath Print®) to capture and measure volatile organic compounds (VOCs) in breath samples from women who have a pelvic mass and will be having surgery. The ultimate goal is to develop a screening test for ovarian cancer. We expect that study will take approximately 45 minutes and breath samples will be obtained before and after surgery.

The main purpose of this study is to see how safe and tolerable CNP-103 is for people with type 1 diabetes. CNP-103 is a nanoparticle (a tiny particle) containing special beta cell proteins. In each group of adults and teens, participants will be assigned by chance (like flipping a coin) to receive either CNP-103 or placebo (like CNP-103 but contains salt water). Participants will have a 66% chance of receiving CNP-103 and a 33% chance of receiving placebo. The total duration of participation from the first Screening visit until the last assessment is approximately 208 days.

This retrospective, longitudinal project is to collect certain demographic and clinical health status information for entry into the CF Foundation Patient Registry (also known as PortCF). The registry has played an important role in CF research and will continue to do so. In addition, much of the same information is entered into the University of Minnesota Cystic Fibrosis Center Research Database. This patient database has been maintained since 1975.

The purpose of this study is to describe current knowledge and opinions about anal cancer screening among men who have sex with men (MSM), as well as their experience receiving guideline-compliant care aimed at anal cancer risk reduction using a large-scale survey disseminated via social media.

The overall goal of this study is to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, and to find out what effects, good and/or bad, the drug gilteritinib has when given with chemotherapy to children and young adults with newly diagnosed AML and the FLT3/ITD mutation or non-ITD FLT3 activating mutations.